INmune Bio Inc reports results for the quarter ended in December - Earnings Summary

Inmune Bio

02/03/2023 23:47

* INmune Bio Inc  INMB.OQ  reported a quarterly adjusted
loss
of 32 cents​​ per share for the quarter ended in December. The
mean expectation of two analysts for the quarter was for a loss
of 48 cents per share.
    * Revenue fell 40.5% to $97.00 thousand from a year ago;
analysts
expected zero. 
    * INmune Bio Inc's reported EPS for the quarter was a loss
of 32
cents​.
    * The mean earnings estimate of analysts had risen by
about 28% in
the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * INmune Bio Inc shares had risen by 47.2% this quarter.
    * The company reported a quarterly loss of $5.83 million.
    * Wall Street's median 12-month price target for INmune Bio
Inc is
$18.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data March 2
at 11:47 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.48          -0.32          Beat
 Sep. 30 2022      -0.52          -0.43          Beat
 Jun. 30 2022      -0.50          -0.38          Beat
 Mar. 31 2022      -0.64          -0.39          Beat